{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-039357","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2022-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.242701+00:00","generated_at":"2026-06-27T08:24:25.580312+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"REGENXBIO RGX-314 Phase II ALTITUDE: 47% patients achieve ≥2-step DRSS improvement at 6 months vs 0% control","bullets":["47% of RGX-314 patients in Cohort 1 showed ≥2-step DRSS improvement at 6 months vs 0% control; up from 33% at 3 months.","No drug-related serious adverse events or intraocular inflammation in 15 patients at 6 months; therapy well tolerated.","Among NPDR patients (severity 47-53), 57% achieved ≥2-step improvement; among PDR patients, 38% achieved improvement.","Enrollment ongoing for Cohorts 2 (5x10^11 GC/eye) and 3 (NAb-positive patients) with no prophylactic corticosteroid use."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-039357","json":"https://secwatch.observer/filing/0001193125-22-039357.json","markdown":"https://secwatch.observer/filing/0001193125-22-039357.md","text":"https://secwatch.observer/filing/0001193125-22-039357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312522039357/0001193125-22-039357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312522039357/d312888d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T08:24:25.580312+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}